FIM
AMRI

Freedom Investment Management’s Albany Molecular Research Inc AMRI Stock Holding History

Freedom Investment Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15,854
Closed -$297K – 1131
2016
Q4 		$297K Sell
15,854
-3,681
-19% -$62.6K 0.02% 700
2016
Q3 		$323K Buy
19,535
+102
+0.5% +$1.51K 0.02% 600
2016
Q2 		$261K Buy
+19,433
New +$283K 0.02% 642

Other funds holding AMRI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Freedom Investment Management's AMRI Position: Q1 2017 in Review

Freedom Investment Management sold out of Albany Molecular Research Inc (AMRI) in Q1 2017, closing a stake of 15,854 shares — an estimated $297K sold.

Freedom Investment Management first reported a position in AMRI in Q2 2016 and held it in 3 quarters. The position peaked at $323K in Q3 2016. 139 funds tracked by Wall St. Rank hold AMRI as of Q1 2017.

  • Freedom Investment Management reported no remaining Albany Molecular Research Inc position as of Q1 2017 after selling out during the quarter.
  • Freedom Investment Management sold 15,854 Albany Molecular Research Inc shares in Q1 2017, an estimated $297K.
  • Freedom Investment Management first reported a position in Albany Molecular Research Inc in Q2 2016 and held it in 3 quarters.
  • Freedom Investment Management's Albany Molecular Research Inc position peaked at $323K in Q3 2016.
  • 139 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2017.

Based on Freedom Investment Management's 13F filing for Q1 2017, filed 2 May 2017.